Abstract

The identification of prognostic biomarkers and their underlying mechanisms of action remain of great interest in breast cancer biology. Using global miRNA profiling of 71 lymph node-negative invasive ductal breast cancers and 5 normal mammary epithelial tissues, we identified miR-449a to be highly overexpressed in the malignant breast tissue. Its expression was significantly associated with increased incidence of patient relapse, decreased overall survival, and decreased disease-free survival. In vitro, miR-449a promoted breast cancer cell proliferation, clonogenic survival, migration, and invasion. By utilizing a tri-modal in silico approach for target identification, Cysteine-Rich Protein 2 (CRIP2; a transcription factor) was identified as a direct target of miR-449a, corroborated using qRT-PCR, Western blot, and luciferase reporter assays. MDA-MB-231 cells stably transfected with CRIP2 demonstrated a significant reduction in cell viability, migration, and invasion, as well as decreased tumor growth and angiogenesis in mouse xenograft models. Our data revealed that overexpression of miR-449a suppresses CRIP2, which then affects the tumor vasculature, likely via NF-κB/p65 complex-mediated transcription of VEGF. These finding define an oncogenic function of miR-449a in human breast cancer, and highlight the importance of this pathway in driving aggressive behaviour.

Highlights

  • MicroRNAs are a class of 17-22 nt non-coding RNAs that suppress other RNAs, and are master regulators of diverse cellular processes [1]

  • Overexpression of miR-449a was associated with tumor recurrence in lymph node-negative (LNN) breast cancer

  • Taqman Low Density Array (TLDA) miRNA profiling demonstrated that miR-449a expression was significantly increased in pre-treatment primary LNN invasive ductal breast cancer samples (n=71) relative to normal mammary epithelial tissues (n=5) (p=0.042; Figure 1A)

Read more

Summary

Introduction

MicroRNAs (miRNAs; miRs) are a class of 17-22 nt non-coding RNAs that suppress other RNAs, and are master regulators of diverse cellular processes [1]. The abnormal expression of various miRNAs has been clearly demonstrated in a wide range of human malignancies, including leukemias and lymphomas [2], as well as colorectal [3], hepatocellular [4], head and neck [5], and breast cancers [6]. These irregular expression profiles have been phenotypically linked to increased proliferation, migration, and invasion [2, 7], with associated chemoand radio-resistance [8]. Identifying a prognostic biomarker capable of stratifying patients into clinically informative treatment categories would possibly benefit the 255,000 Americans and Canadians diagnosed with IDC each year [13, 14]

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call